A5017664557- MicroRNA in disease regulation
- Melanoma and MAPK Pathways
- Cancer-related molecular mechanisms research
- Computational Drug Discovery Methods
- DNA Repair Mechanisms
- Circular RNAs in diseases
- RNA modifications and cancer
- CRISPR and Genetic Engineering
- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
- Protein Degradation and Inhibitors
- Cancer Research and Treatments
- Cutaneous Melanoma Detection and Management
- RNA Research and Splicing
- Mitochondrial Function and Pathology
- RNA regulation and disease
- PI3K/AKT/mTOR signaling in cancer
- Virus-based gene therapy research
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Nanoplatforms for cancer theranostics
- Protein Tyrosine Phosphatases
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
National Research Council
2015-2025
Istituto di Fisiologia Clinica
2015-2025
University of Pisa
2018-2025
National Research Council
2025
Expro (United Kingdom)
2025
Istituto per lo Studio e la Prevenzione Oncologica
2022
Tumour Institute of Tuscany
2015-2017
Beth Israel Deaconess Medical Center
2008-2015
Cancer Genetics (United States)
2008-2013
New York University
2011-2012
A microRNA network regulates the tumor suppressor PTEN in prostate cancer.
Abstract The recalcitrance of Mycobacterium tuberculosis to antibiotic treatment has been broadly attributed the impermeability organism’s outer mycomembrane. However, studies that support this inference have indirect and/or reliant on bulk population measurements. We previously developed P eptidoglycan A ccessibility C lick- M ediated ssessme N t (PAC-MAN) method covalently trap azide-modified small molecules in peptidoglycan cell wall live mycobacteria, after they traversed Using PAC-MAN...
// Marianna Vitiello 1, 2 , Andrea Tuccoli 1 Romina D’Aurizio 3 Samanta Sarti 4 Laura Giannecchini Simone Lubrano Marranci Monica Evangelista Silvia Peppicelli 5 Chiara Ippolito 6 Ivana Barravecchia 7 Elena Guzzolino Valentina Montagnani 8 Michael Gowen 9 Elisa Mercoledi Alberto Mercatanti Comelli Salvatore Gurrieri Lawrence W. Wu 10 Omotayo Ope Keith Flaherty 11 Genevieve M. Boland Marc R. Hammond Kwong 12 Mario Chiariello 2, 13 Barbara Stecca Gao Zhang Alessandra Salvetti 14 Debora...
Effective excretion of nanostructured noble metals is still one the most challenging bottlenecks for their employment in clinical practice. Besides persistence issue, translation inorganic nanomaterials also affected by a bewildering lack investigations regarding quantitative biokinetics. Here, we have quantitatively correlated chemical nature three interesting biomedical applications to biosafety and biokinetics in, respectively, zebrafish murine models. Gold, silver, platinum...
MicroRNAs (miRNAs) are short 20–22 nucleotide RNA molecules that act as negative regulators of gene expression via translational repression: they have been shown to play a role in development, proliferation, stress response, and apoptosis. The transcriptional regulator LRF (Leukemia/lymphoma Related Factor) has prevent p19ARF transcription consequently inhibit senescence mouse embryonic fibroblasts (MEF). Here we report, for the first time, is post-transcriptionally regulated by miR-20a....
Several reports have demonstrated a role for aberrant NOTCH signaling in melanoma genesis and progression, prompting us to explore if targeting this pathway is valid therapeutic approach against melanoma. We targeted using RO4929097, novel inhibitor of gamma secretase, which key component the enzymatic complex that cleaves activates NOTCH. The effects RO4929097 on oncogenic stem cell properties panel lines were tested both vitro vivo, xenograft models. In human primary lines, decreased...
Superficial spreading melanoma (SSM) and nodular (NM) are believed to represent sequential phases of linear progression from radial vertical growth. Several lines clinical, pathologic, epidemiologic evidence suggest, however, that SSM NM might be the result independent pathways tumor development. We utilized an integrative genomic approach combines single nucleotide polymorphism array (6.0; Affymetrix) with gene expression (U133A 2.0; examine molecular differences between NM. Pathway...
Attenuated Listeria monocytogenes (Lmat-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lmat-LLO causes ROS production and, turn, apoptotic killing of wide variety melanoma cells, irrespectively their stage, mutational status, sensitivity to BRAF inhibitors or degree stemness. We also that, when administered the therapeutic setting Braf/Pten genetically engineered mice, strong decrease size volume primary tumors, as well reduction...
Previous reports have demonstrated a role for hedgehog signaling in melanoma progression, prompting us to explore the therapeutic benefit of targeting this pathway melanoma. We profiled panel human cell lines and control melanocytes altered expression members determined consequences both genetic pharmacological inhibition activator Smoothened (SMO) melanoma, vitro vivo. also examined relationship between mediators survival well-characterized cohort metastatic patients with prospectively...
The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression not completely understood. Taking advantage RNA-seq data more than 4800 patients belonging to 9 different types, we show that mRNA exists pool 3 isoforms (reference BRAF, BRAF-X1, BRAF-X2) differ in last part their coding sequences, well length (BRAF-ref: 76 nt; BRAF-X1 BRAF-X2: up 7 kb) sequence 3'UTRs. levels BRAF-ref BRAF-X1/X2 are inversely correlated, while most...